Portugal · Delayed Price · Currency is EUR The Navigator Company Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw resilient results despite severe weather and geopolitical volatility, with diversification driving 40% of EBITDA from tissue and packaging. Price increases and cost discipline offset operational disruptions, while strategic investments and a strong balance sheet support future growth.
Fiscal Year 2025
-
Despite a challenging year with sharp price declines and weak demand, diversified operations in tissue and packaging drove resilient earnings and market share gains. Strategic investments and efficiency initiatives position the group for growth and margin improvement in 2026.
-
Resilience in volatile markets was achieved through diversification, cost optimization, and operational excellence, with strong performance in tissue and packaging offsetting weaker pulp and paper prices. Financial discipline and sustainability investments underpin a robust outlook, despite ongoing macroeconomic risks.
-
Turnover reached EUR 1.019 billion in H1 2025, with strong growth in tissue and packaging segments and EBITDA of EUR 216 million, down 28% year-on-year. The company maintained a robust financial position, advanced key investments, and is proactively managing risks amid trade and market volatility.
-
Solid Q1 performance with 2% revenue growth and stable EBITDA margin, driven by strong tissue and packaging segments. Strategic investments and diversification support resilience amid volatile energy costs and market uncertainty. Flexible packaging and tissue now account for 45% of sales.
Fiscal Year 2024
-
Turnover rose 7% to EUR 2.09 billion, with EBITDA at EUR 547 million and net profit up 4%. Business diversification, cost reductions, and international expansion drove strong results, while investments in sustainability and innovation continued. Dividend of EUR 175 million proposed.
-
Strong nine-month results driven by tissue and packaging growth, cost reductions, and resilient pricing, with net profit up 20% year-on-year and robust liquidity. Outlook remains cautiously optimistic amid geopolitical uncertainty, with sector demand and prices expected to recover.
-
H1 2024 saw 9% revenue and 18% EBITDA growth, driven by strong pricing, cost reductions, and business mix optimization. The Accrol acquisition expanded the tissue segment, while robust liquidity and a low Net Debt-to-EBITDA ratio supported ongoing investments. Sustainalytics ranked the company as the lowest ESG risk in its sector.